Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Gross Margin (2016 - 2025)

Historic Gross Margin for OptimizeRx (OPRX) over the last 13 years, with Q3 2025 value amounting to 67.2%.

  • OptimizeRx's Gross Margin rose 40900.0% to 67.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.31%, marking a year-over-year increase of 27100.0%. This contributed to the annual value of 64.45% for FY2024, which is 44700.0% up from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Gross Margin is 67.2%, which was up 40900.0% from 63.83% recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Gross Margin registered a high of 68.15% during Q4 2024, and its lowest value of 54.54% during Q1 2021.
  • Over the past 5 years, OptimizeRx's median Gross Margin value was 61.98% (recorded in 2024), while the average stood at 61.26%.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 86300bps in 2021, then crashed by -76800bps in 2023.
  • Quarter analysis of 5 years shows OptimizeRx's Gross Margin stood at 61.0% in 2021, then rose by 4bps to 63.37% in 2022, then decreased by -1bps to 62.89% in 2023, then rose by 8bps to 68.15% in 2024, then decreased by -1bps to 67.2% in 2025.
  • Its Gross Margin stands at 67.2% for Q3 2025, versus 63.83% for Q2 2025 and 60.85% for Q1 2025.